Early OCT angiography changes of type 1 CNV in exudative AMD treated with anti-VEGF.


Journal

The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041

Informations de publication

Date de publication:
01 2019
Historique:
received: 15 12 2017
revised: 04 02 2018
accepted: 05 03 2018
pubmed: 24 3 2018
medline: 21 9 2019
entrez: 24 3 2018
Statut: ppublish

Résumé

To investigate, with optical coherence tomography angiography (OCTA), short-term changes of type 1 choroidal neovascularisation (CNV), secondary to exudative age-related macular degeneration, after anti-vascular endothelial growth factor (VEGF) treatment. Patients affected by type 1 CNV treated with intravitreal anti-VEGF were consecutively enrolled. All patients underwent OCTA examination before and 48 hours after anti-VEGF treatment. Quantitative and qualitative vascular and morphological macular changes were evaluated. Sixteen eyes were included (11 treated with aflibercept and 5 with ranibizumab). Both CNV mean area and pigment epithelium detachment significantly reduced (p=0.0004 and p=0.0007, respectively) after treatment. Cystoid macular oedema (four eyes) decreased in all cases. Neuroretinal detachment (13 eyes) decreased in 85% of cases (11 eyes). Fine CNV vessels density decreased in 75% (12 eyes), whereas larger CNV vessels density remained stable in 66.7% (10 eyes), choroidal flow void signal (7 eyes at baseline) increased in 42.9% (3 eyes) of them and remained stable in 57.1% (4 eyes). Interoperator reproducibility for OCT examination was good for all measurements (intraclass correlation coefficient>0.65). Early remodelling of type 1 CNV network after treatment may be non-invasively and reproducibly analysed by means of OCTA. Choroidal perfusion impairment, choroidal flow void signal, surrounding CNV may change during treatment.

Identifiants

pubmed: 29567794
pii: bjophthalmol-2017-311752
doi: 10.1136/bjophthalmol-2017-311752
doi:

Substances chimiques

Angiogenesis Inhibitors 0
Vascular Endothelial Growth Factor A 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

67-71

Informations de copyright

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Elisabetta Pilotto (E)

Department of Ophthalmology, University of Padova, Padova, Italy.

Luisa Frizziero (L)

G.B. Bietti Foundation, IRCCS, Rome, Italy.

Anna Rita Daniele (AR)

Department of Ophthalmology, University of Padova, Padova, Italy.

Enrica Convento (E)

Department of Ophthalmology, University of Padova, Padova, Italy.

Evelyn Longhin (E)

Department of Ophthalmology, University of Padova, Padova, Italy.

Francesca Guidolin (F)

Department of Ophthalmology, University of Padova, Padova, Italy.

Raffaele Parrozzani (R)

Department of Ophthalmology, University of Padova, Padova, Italy.

Fabiano Cavarzeran (F)

Department of Ophthalmology, University of Padova, Padova, Italy.

Edoardo Midena (E)

Department of Ophthalmology, University of Padova, Padova, Italy.
G.B. Bietti Foundation, IRCCS, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH